HealthRX.com · Printable supplement log
Creatine and MOTS-c-labelled product timeline for reading kidney results
Creatine can raise serum creatinine without a matching change in filtration, and MOTS-c has no human kidney data. A dated record of what changed, and when, lets a clinician read your results without guessing at causes.
What changed, and when
One row for every start, stop, loading phase or change in amount of either product.
| Date | What changed | Exact product and lot | Daily amount or directions | Notes |
|---|---|---|---|---|
| Creatine started | ||||
| MOTS-c-labelled product started | ||||
Kidney-marker results
Copy the marker, the result and the eGFR equation from each lab report.
| Date | Marker and result | eGFR equation used | Hydration, illness, exercise or diet that week | Medicines started or stopped |
|---|---|---|---|---|
Symptoms
| Date it started | Symptom | Date it resolved |
|---|---|---|
What the evidence supports
- In a 2026 meta-analysis of randomized creatine studies, serum creatinine was 0.13 mg/dL higher on average, while pooled urea and eGFR did not differ from control.[1]
- The same authors call for randomized trials lasting beyond 1 year to judge kidney safety.[1]
- FDA's July 2026 review identified no clinical studies with pharmacokinetic data for MOTS-c.[2]
- The registered MOTS-c trial compares MOTS-c with placebo; it has no creatine arm.[3]
Questions to ask when a kidney result comes back
- Was this eGFR calculated from creatinine, cystatin C or both?
- Could my creatine use explain the change in creatinine?
- Would a different filtration marker help in my case?
- What result would make you repeat the test, and when?
- What should I tell you before the next blood draw?
Sources for the facts on this sheet
- Tsiaras A, Loufopoulos G, Theodoridis X, et al. The Effect of Creatine Supplementation on Kidney Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Ren Nutr 2026. PMID 42035842. https://pubmed.ncbi.nlm.nih.gov/42035842/
- U.S. Food and Drug Administration. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. Accessed 2026-10-18. https://www.fda.gov/media/193347/download
- U.S. National Library of Medicine, ClinicalTrials.gov (API v2 record). NCT07505745: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity. Accessed 2026-10-18. https://clinicaltrials.gov/api/v2/studies/NCT07505745
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.